Zainuddin Norafiza, Berglund Mattias, Wanders Alkwin, Ren Zhi-Ping, Amini Rose-Marie, Lindell Monica, Kanduri Meena, Roos Göran, Rosenquist Richard, Enblad Gunilla
Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden.
Leuk Res. 2009 Jan;33(1):60-6. doi: 10.1016/j.leukres.2008.06.022. Epub 2008 Aug 15.
Presence of TP53 mutations has been associated with poor prognosis in diffuse large B-cell lymphoma (DLBCL), although this has remained controversial. The TP53 codon 72 polymorphism has shown negative impact on cancer survival, but this has not been analyzed in DLBCL. Furthermore, the MDM2 SNP309 has been associated with earlier age of onset in DLBCL. Here, we investigated the clinical impact of TP53 mutations, MDM2 SNP309 and TP53 codon 72 polymorphisms on survival in DLBCL of germinal center (GC) and non-GC subtypes. Thirteen of the 102 (12.7%) patients displayed TP53 mutations. Overall, TP53 mutations had a significant effect on lymphoma-specific survival (LSS, P=0.009) and progression-free survival (PFS, P=0.028). In particular, inferior survival was observed in TP53-mutated DLBCLs of GC subtype (LSS, P=0.002 and PFS, P=0.006). Neither MDM2 SNP309 nor the TP53 codon 72 polymorphism had an impact on age of onset or survival. Altogether, our data suggests that TP53 mutations are associated with poor outcome in GC-DLBCL patients.
TP53突变的存在与弥漫性大B细胞淋巴瘤（DLBCL）的不良预后相关，尽管这一点仍存在争议。TP53密码子72多态性已显示对癌症生存有负面影响，但尚未在DLBCL中进行分析。此外，MDM2 SNP309与DLBCL的发病年龄较早有关。在此，我们研究了TP53突变、MDM2 SNP309和TP53密码子72多态性对生发中心（GC）和非GC亚型DLBCL患者生存的临床影响。102例患者中有13例（12.7%）出现TP53突变。总体而言，TP53突变对淋巴瘤特异性生存（LSS，P = 0.009）和无进展生存（PFS，P = 0.028）有显著影响。特别是，在GC亚型的TP53突变DLBCL中观察到较差的生存率（LSS，P = 0.002；PFS，P = 0.006）。MDM2 SNP309和TP53密码子72多态性均对发病年龄或生存无影响。总之，我们的数据表明TP53突变与GC-DLBCL患者的不良预后相关。
Zotero 插件